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Précis (35 words) 42 
This study demonstrates that the clinical phenotype in direct immunofluorescence (DIF) positive and 43 
negative ocular MMP is very similar. This finding supports the rationale for the recognition of the 44 
diagnosis of DIF negative ocular MMP.  45 
  46 
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Abstract (348 of a 350 word limit) 47 
 48 
Objective: This study explored the validity of the First International Consensus on Mucous Membrane 49 
Pemphigoid (MMP) guidance which recommends that clinically indistinguishable patients, who have 50 
direct immunofluorescence (DIF) negative biopsies, be excluded from a diagnosis of MMP.  51 
Misdiagnosis, or delayed diagnosis, of MMP with ocular involvement leads to the inappropriate use of 52 
topical therapy, the standard of care for causes of cicatrising conjunctivitis other than MMP, rather than 53 
systemic immunomodulatory therapy; resulting in irreversible clinical deterioration in MMP patients.  54 
 55 
Design: Prospective cross-sectional study  56 
 57 
Subjects and controls: 73 patients meeting the clinical criteria of ocular MMP, including those with 58 
positive and negative DIF findings.  59 
 60 
Testing: A case report form was used to collect demographic details, the clinical history, and the 61 
results of a detailed clinical assessment by ophthalmologists, otolaryngologists, dermatology and oral 62 
medicine specialists. All anatomical sites, potentially affected by MMP, were examined apart from the 63 
oesophagus (and larynx in a subset). DIF results were recorded.   64 
 65 
Main outcome measures: Differences between DIF positive and negative patients in demography, 66 
sites of involvement, and disease severity as determined by the degree of: conjunctival scarring (using 67 
Tauber staging), central corneal disease (vessels, scarring, ulceration and conjunctivalisation), history 68 
of conjunctival or lid surgery, and requirement for systemic immunotherapy at the time of screening.  69 
 70 
Results: 73 patients with ocular MMP were recruited of whom 20/73 (27.4%) had ocular only disease. 71 
There was no significant demographic or clinical difference between patients with positive and 72 
negative DIF results. This finding included differences in disease severity for which the only 73 
significant difference was that of more severe central corneal disease in DIF negative patients. 74 
Asymptomatic disease at different sites was frequent. 75 
 76 
Conclusions: These findings do not support the classification of DIF negative patients, meeting the 77 
clinical criteria for ocular MMP, as having a different disease. This category of patients should be 78 
accepted as having DIF negative MMP, for clinical management purposes, with patients having 79 
inflamed eyes being treated with systemic immunomodulatory therapy. The frequent finding of 80 
asymptomatic ocular, oral and nasopharyngeal MMP is clinically significant and implies that these 81 
sites should be routinely screened in asymptomatic patients.   82 
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INTRODUCTION 83 
Mucous membrane pemphigoid (MMP), previously known as “cicatricial pemphigoid”, refers to a 84 
heterogenous group of autoimmune subepidermal blistering disorders that affect mucous membranes at 85 
the orifices, including the ocular, oral, nasopharyngeal, tracheal, oesophageal, anogenital and 86 
genitourinary; the skin may or may not be affected.1 Inflammation is associated with progressive 87 
cicatrisation (scarring) at all sites, with the exception of the oral mucosa, where scarring is uncommon. 88 
The reported incidence of MMP is approximately 1.16 to 2.0 per million population2,3 and prevalence 89 
1:40,000.4 Approximately 70% of patients with MMP have ocular involvement (ocular MMP).5,6  90 
Ocular MMP, characterised by relapsing conjunctivitis with progressive conjunctival cicatrisation, is 91 
the commonest cause of cicatrising conjunctivitis in the United Kingdom with an incidence of 0.8 per 92 
million population.7 Although the mean age of onset of  ocular MMP is 65 years,8,9 it also occurs in 93 
children and young adults in whom the disease is more aggressive.10-12 The current standard of care for 94 
patients with symptomatic ocular MMP is systemic immunomodulatory therapy, because of the failure 95 
of topical therapies in MMP affecting this site.11,13-15 However, the response to systemic 96 
immunomodulatory therapy is variable, and side effects are common.8,16 Chronic discomfort is normal, 97 
and 20% of cases become bilaterally blind due to ocular surface failure, corneal vascularisation, and 98 
corneal opacification.16,17  99 
 100 
Early diagnosis and treatment are essential to reduce sight-threatening complications in ocular MMP. It 101 
is recommended that a clinical diagnosis of MMP is made only when the clinical criteria for MMP at 102 
any site are accompanied by laboratory evidence of an antibody mediated disease at the epithelial 103 
basement membrane.1 The latter requires a biopsy from any mucosal site (not necessarily ocular), or 104 
from skin, demonstrating  linear deposition of IgG and/or IgA and/or complement at the epithelial 105 
basement membrane (BM) using a direct immunofluorescence (DIF) technique.1,18-20  106 
 107 
Ocular MMP limited to the eye (ocular only MMP) has varied from 14/74 (19%) to 26/86 (30%) 108 
depending on the definition in one study9 and 18/50 (36%) in another.7 However, it is recognised that 109 
in ocular only MMP, half of the patients with conjunctival disease typical of MMP, have had 110 
intermittent or repeatedly negative DIF.9,15,21-24 This may result in delayed or incorrect diagnosis. 111 
Because the standard of care for cicatrising conjunctivitis, other than that caused by MMP, is with 112 
topical as opposed to systemic immunomodulatory therapy, these patients can progress irreversibly. 113 
For these reasons we have previously proposed that a clinical diagnosis of ocular only MMP, in 114 
patients with a negative biopsy result, can be made in patients meeting the clinical criteria for MMP, 115 
after excluding other causes of conjunctival scarring.8,25 This proposal has not been widely accepted as 116 
it is counter to the guidance in the First International Consensus on Mucous Membrane Pemphigoid,1 117 
which recommends that clinically indistinguishable patients, who have direct immunofluorescence 118 
(DIF) negative biopsies, be excluded from a diagnosis of MMP. Negative immunopathology findings 119 
have been thought to occur in this group of patients because antibody levels are low, and frequently 120 
undetectable, because the sensitivity of DIF in the conjunctiva is low for reasons that are uncertain23 or 121 
because the disease is not MMP although alternative diagnoses have not been offered.1 It is also 122 
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possible that BM autoantibodies may be absent in a subset of MMP patients who have developed 123 
disease due to an autoreactive T cell mediated immune response, without the development of 124 
detectable autoantibodies.15 125 
 126 
This prospective cross sectional study was designed to explore the hypothesis that DIF negative ocular 127 
MMP might represent a different disease subset from those with a positive DIF results, by exploring 128 
differences in the phenotype of these patients. Parameters compared included the demography, 129 
distribution of sites of involvement, severity, and activity of the ocular disease. Patients with 130 
asymptomatic disease at different sites were also recorded.  131 
 132 
METHODS 133 
This was a prospective cross-sectional study on a cohort of patients diagnosed with MMP. The study 134 
protocol has been approved by the UK National Research Ethics Service (Reference 09/H0721/54). 135 
The study adhered to the tenets of the Declaration of Helsinki.  136 
 Patients diagnosed with MMP, at any site, were identified from databases of existing patients, 137 
and from new referrals, at two London Clinics (Moorfields Eye Hospital NHS Foundation Trust, 138 
Corneal and External Disease Clinics and Guys and St Thomas’s NHS Foundation Trust, Oral 139 
Medicine and Dermatology Clinics). Patients had the following sites assessed for the presence of 140 
MMP: ocular, oral, skin, anogenital and nasopharyngeal by the relevant specialists. Nasopharyngeal 141 
screening was carried out in the otolaryngology departments at both Guys and St Thomas’s NHS 142 
Foundation Trust and at the Royal National Ear Nose Throat Hospital. The results of previous DIF tests 143 
were recorded as positive or negative. If DIF had not been carried out previously, biopsies from 144 
affected mucosa or skin were taken and processed for DIF using standard techniques.26 We were 145 
unable to standardize the DIF method because many patients had been referred with DIF results from 146 
biopsies that had performed locally. Details of the DIF findings were not available for all the patients 147 
and were not recorded. For this study, the diagnosis of ocular MMP was based on clinical findings 148 
typical of ocular MMP (after exclusion of other causes of scarring conjunctivitis),8,15 regardless of DIF 149 
results. 150 
 Data collection used a case report form designed for this study (Supplementary Appendix 1, 151 
online). A clinical history was taken from all patients, focusing on their general health and the 152 
involvement of other anatomical sites by MMP. Other information obtained included demographic 153 
details, a medical history of autoimmune diseases or malignancy, and the ophthalmic history. 154 
 All patients then underwent a detailed clinical assessment by a multi-disciplinary team of 155 
ophthalmologists, otolaryngologists and a dermatology and oral medicine specialist. All anatomical 156 
sites that can potentially be affected by MMP, apart from the oesophagus (and larynx in a subset of 157 
patients), were screened for signs of disease. Fourteen patients declined nasopharyngeal and anogenital 158 
examination.  When a patient declined screening of particular anatomical sites (apart from the eye), site 159 
involvement was determined from the disease history.  History is necessary because for most oral 160 
disease cases, and some with nasopharyngeal involvement, there is no residual scarring to indicate a 161 
disease episode in patients in remission.  Table 1a summarises the sites assessed for involvement by 162 
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MMP and the positive screening criteria for each site. Table 1b describes the classification used MMP 163 
involvement of sites using both screening and history.  164 
Ophthalmological Assessment 165 
During ophthalmological assessment, the best corrected visual acuity for each eye was recorded in 166 
Snellen’s notation. A score was given to each eye according to its visual acuity: 1=6/7.5 or better, 167 
2=6/9-6/12, 3=6/18-6/36, 4=6/60 or worse, 5=3/60-count fingers, 6=hand movements, 7=perception of 168 
light, and 8=no perception of light. For each patient, the score from the eye with the worst visual acuity 169 
was used for analysis.    170 
 Each eye was given an inflammation scoring methodology in the case report form 171 
(Supplementary Appendix 1 online). The score for each quadrant of bulbar conjunctiva ranged from 0-172 
4 giving a maximum score of 16 for each eye, and of 32 for both eyes. A patient was defined as having 173 
significant ocular inflammation if the total score was 5 or more: minimal levels of conjunctival 174 
inflammation may be due to blepharoconjunctivitis or dry eye rather than to underlying MMP related 175 
inflammation. 176 
 Tauber staging was used to assess the extent of conjunctival scarring.27 All patients had 177 
conjunctival scarring by definition. Severe scarring was defined as Tauber stage greater than IIb (lower 178 
fornix shortening more than 25%) or Tauber stage greater than IIIb (presence of lower lid 179 
symblepharon more than 25%).  180 
 Amongst the other indices of severity assessed were corneal pathologies expected to reduce 181 
vision: vascularisation, scarring, ulceration, and conjunctivalisation. Severe disease was classified as 182 
any of these involving the central 5mm of cornea (pupillary zone). 183 
 Ocular discomfort as reported by patients were graded as: none, tolerable, moderate, or severe. 184 
The extent to which vision affects daily activities as reported by patients were graded as: unaffected, 185 
adequate for needs, and restricts activity. 186 
Statistical analysis 187 
Data were managed in Excel (Microsoft) and analysed using Statistical Program for Social Sciences 188 
(SPSS©) Version 22 (2013 IBM© US). Differences in the distribution of categorical variables between 189 
groups were analysed using the Chi-squared test. Fisher’s exact test was used when expected 190 
frequencies of cells less than 5 were present. For continuous variables, differences in distributions 191 
between DIF positive and DIF negative groups were analysed using the Mann-Whitney U test. 192 
Significance level was set at p <0.05. 193 
 194 
RESULTS  195 
112 patients with a diagnosis of MMP were recruited. 73/112 (65.2%) patients screened had ocular 196 
involvement and it is these that have been evaluated for this study. The median time from the diagnosis 197 
of MMP to the study examination was 104 months (interquartile range [IQR] 54 – 146 months). The 198 
data for each patient are included in Supplementary Table 1 online. 199 
 200 
Patient characteristics and direct immunofluorescence findings   201 
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The presenting features of the 73 patients with ocular MMP are summarised in Table 2. There were no 202 
significant demographic or clinical differences between DIF positive and DIF negative patients. 203 
 204 
Differences between patients grouped by differences in involvement at different sites 205 
Table 3 describes the sites involved in this group of ocular MMP patients and compares their 206 
demographic characteristics, the numbers using systemic immunotherapy at the time of screening, 207 
those who had asymptomatic disease identified at screening, and the DIF results. Asymptomatic 208 
disease at different sites was common and identified in 8/19 (42.1%) patients with ocular and oral 209 
disease and 6/10 (60.0%) patients with ocular, oral and nasopharyngeal disease. Of those with evidence 210 
of mucosal involvement in the nasopharynx, 6/10 (60%) were asymptomatic. Compared to patients in 211 
other groups, patients who had ocular only involvement were more likely to have a negative DIF status 212 
(p=0.03). Figure 1 describes the patients grouped by different sites of involvement: 20/73 (27.4%) had 213 
ocular only disease, 19/73 (26.0%) had ocular and oral disease, 10/73 (13.7%) had ocular, oral and 214 
nasopharyngeal disease, and 24/73 (32.9%) had ocular disease with multiple extraocular sites involved 215 
in various other combinations. The anatomical sites involved were classified using the criteria 216 
described in Table 1.  217 
 218 
Severity of disease comparison in DIF positive versus DIF negative ocular MMP patients   219 
Table 4 and Figure 2 compare the severity of disease in having positive and negative DIF results. For 220 
all cases of ocular disease there was a trend to more severe disease in DIF negative patients, with 221 
differences that were statistically significant for the presence of central corneal disease.  222 
 For the 19 patients with ocular only MMP, disease severity indices (Table 4) were evenly 223 
balanced with trends to less conjunctival scarring in the DIF negative group but worse corneal disease, 224 
and a very similar requirement for systemic immunotherapy.  225 
 Visual acuity scores were statistically significantly worse in DIF negative patients (p=0.03). 226 
However, due to clinically significant ocular co-morbidities in these patients, visual acuity scores can 227 
be difficult to interpret. There was no statistically significant difference in the proportion of patients 228 
who reported restriction of daily activities due to poor vision (p=0.258). Reported ocular discomfort 229 
scores were similar in both DIF positive and DIF negative patients (p=0.104). 230 
 231 
 232 
DISCUSSION  233 
 234 
This study of patients having ocular MMP were also assessed for the presence of MMP at extraocular 235 
sites. Limitations of this study are the inclusion of patients who declined screening and examination of 236 
particular anatomical sites, such as nasopharyngeal and anogenital regions, for whom the assumption 237 
was made that these sites were uninvolved in the absence of a history for MMP at that site. Although 238 
the clinical signs and scarring parameters in the case report form used in this study were based on 239 
previously published systems,27 these are not validated. There is currently no validated scheme for 240 
measuring the severity and activity of disease in scarring conjunctivitis. In addition, this was a cross 241 
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sectional study so that, although we could record the requirement for systemic immunosuppressive 242 
therapy at the time of the study, we could not assess the effect of treatment on outcomes. However, in 243 
our previous study the datasheet evaluating long term outcomes is included in the supplementary 244 
data.16 We have used this to assess the effect of the first treatment episode in DIF positive and negative 245 
ocular MMP patients respectively: these data are shown in Supplementary Figure 1 which show no 246 
major differences in the outcomes. Immunosuppressive treatments were administered according to 247 
previously published step-wise regimen.15  248 
 We have shown that a substantial proportion of cases had ocular only disease (20/73 249 
[27.39%]) without involvement of other sites: similar to that in previous reports.7,9,17 We also 250 
confirmed that in this subset with ocular only disease, 11/19 (55%) were significantly less likely 251 
(p=0.03) to have a positive DIF result. This proportion is similar to what has been previously described 252 
for this group of patients.9,15,21-24 Twenty six patients (35.6%) of the overall ocular MMP cohort were 253 
DIF negative. This is the first prospective study to provide a detailed analysis of clinical differences 254 
between patients, meeting clinical criteria of ocular MMP,  irrespective of  their DIF findings. This has 255 
shown that there are few differences between the DIF negative and DIF positive subsets, with two 256 
parameters, central corneal pathology and prior lid or conjunctival surgery, being significantly more 257 
common in the DIF negative group. This evidence provides no support for the classification of DIF 258 
negative MMP as a different disease from DIF positive MMP as has been suggested1 and is in keeping 259 
with findings in two other studies exploring the issue of DIF negative ocular MMP patients23,24.  260 
 This is also the first study, to our knowledge, that has reported the results of screening of 261 
asymptomatic sites in MMP patients. Asymptomatic ocular, oral and nasopharyngeal disease were 262 
frequently identified. This finding is clinically significant as some ocular MMP patients develop 263 
progressive cicatrisation without clinical inflammation,28 discomfort from MMP may be accepted as a 264 
matter of course by patients having oral MMP who can be expected to benefit from appropriate 265 
management. Lastly, asymptomatic tracheal involvement has been reported in a series of patients with 266 
nasopharyngeal disease29 and can lead to severe complications which may benefit from early 267 
identification. 268 
 Our demonstration that, in patients meeting clinical criteria for ocular MMP the direct 269 
immunofluorescence findings do not relate to the clinical phenotype, supports our previous 270 
recommendation that clinical criteria, together with the result of conjunctival biopsies for both routine 271 
histopathology and DIF, can be used to make a definitive diagnosis of DIF negative ocular MMP. This 272 
is justified because the more than 20 other diseases causing conjunctival scarring can be excluded with 273 
a combination of these biopsy results and clinical criteria. Histopathology is needed to exclude ocular 274 
surface tumors whereas DIF is used not only to confirm a diagnosis of MMP, but also to distinguish 275 
MMP from other causes of conjunctival scarring; these include lichen planus, showing shaggy 276 
discontinuous fibrinogen deposits at the BMZ,30-32 and pemphigus having intraepithelial antibodies.1 277 
The infrequent cases of inflammation and progressive scarring, associated with both Stevens Johnson 278 
syndrome and topical medications (following withdrawal of the medication) that are DIF negative 279 
should also be treated in the same way as DIF negative MMP. If DIF is negative then alternative 280 
evidence of autoantibodies to epithelial BM proteins may be available from autoantibody detection, 281 
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using indirect immunofluorescence, ELISA or Western blotting. However these tests are often negative, 282 
and therefore not required for diagnosis using the Consensus criteria;1 in our experience they are also 283 
usually negative in DIF negative patients. Diagnostic criteria for the many causes of cicatrising 284 
conjunctivitis, and a flow chart for this,  have been described in detail in a recent review.15 285 
 Whereas we agree that in ocular only DIF a conjunctival biopsy should be taken for DIF 286 
testing, and that for some purposes, such as the investigation of some aspects of the 287 
immunopathogenesis of conjunctival MMP, tissue should only be used from patients having at least 288 
one positive DIF result33-35, we hope that the diagnosis of DIF negative ocular MMP will be widely 289 
accepted for clinical management purposes. This will allow patients with this condition to access 290 
appropriate therapy without the delays that are currently common, because of failure to meet the 291 
existing diagnostic criteria for MMP affecting other sites.   292 
 Moreover, performing immunofluorescence on small conjunctival samples can be operator-293 
dependent and the interpretation of immunofluorescence results subjective. Thus, technical and 294 
interpretation factors may contribute to both false negative and false positive DIF findings. 295 
Furthermore, the absence of identifiable autoantibodies in some patients with clinical MMP may not 296 
only be due to undetectably low levels of antibody but also suggests the possibility that a subset of 297 
MMP patients have disease that results from a cell mediated response resulting from autoreactive T 298 
cells to epithelial basement membrane proteins, without circulating antibodies. This would parallel the 299 
situation in most other autoimmune diseases which result from variable levels of cellular and 300 
autoantibody driven responses.15 We think that this hypothesis deserves further investigation in MMP. 301 
  302 
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FIGURE LEGENDS 303 
 304 
Figure 1: 305 
Cohort of patients with ocular mucous membrane pemphigoid showing the combinations of sites 306 
(n=73). 307 
  308 
Figure 2: 309 
Direct immunofluroescence (DIF) status and severity of disease showing trends of more severe disease 310 
in 26 DIF negative patients compared to 43 DIF positive patients. 311 
  312 
Supplementary Figure 1: 313 
 Bar graph showing first treatment episode outcomes for biopsy-positive and biopsy-negative patients. 314 
 x-axis: percentage success, qualified success, failure in patients given that agent; y-axis: principal 315 
agent. DIF = direct immunofluorescence; n = no. of patients; *p-values compares distribution of drug 316 
therapies between DIF positive and DIF negative patients, Fisher’s exact (2-sided) test. There were no 317 
significant differences in treatment outcomes between DIF positive and DIF negative patients for all 318 
drug categories combined (p=0.702). 319 
  320 
  321 
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Table 1a Sites assessed for involvement by mucous membrane pemphigoid (MMP) and positive screening criteria for MMP involvement of sites 
Site Sites assessed Positive screening criteria for MMP at each site 
Ocular Lids, conjunctiva and cornea Conjunctival scarring mandatory for diagnosis 
Oral Lips, buccal mucosa, gingivae, tongue, floor of mouth, 
hard palate, oropharynx 
Erythema, ulceration or scarring AND/OR a history of oral MMP (included 
as signs of inactive disease are usually absent because residual scarring is 
uncommon) 
Nasopharyngeal Nasal cavity, nasopharynx, oropharynx, hypopharynx 
and larynx 
Crusting and/or ulceration and/or scarring at each site  
Genital Labia major/minor, vestibule, vagina, glans penis, 
prepuce 
Erosions and/or scarring at any site 
Skin Skin Ulcers and/or scars 
 
Table 1b Classification for mucous membrane pemphigoid involvement of sites by screening and history* 
Ocular only Definitive clinical Screen positive, & no History of non-ocular MMP, & ALL other sites screened and found free of MMP  
Probable clinical Screen positive, & no History of non-ocular MMP, & no MMP in other sites screened but 1 or more other 
sites NOT screened.   
Oral only Definitive clinical Screen positive &/or History of oral MMP, & no History of other site involvement, & ALL other sites 
Screened and found free of MMP.  
Probable clinical Screen positive &/or History of oral MMP, & no History of other site involvement, & no MMP in other sites 
but 1 or more other sites NOT screened.  
Ocular & Oral only Definitive clinical Screen positive ocular & [Screen positive oral OR History of oral], & no History of other site involvement, & 
ALL other sites Screened and found free of MMP.  
Probable clinical Screen positive ocular & [Screen positive oral OR History of oral], & no History of other site involvement, & 
no MMP in other sites but 1 or more other sites NOT Screened.  
Nasopharyngeal   
other sites 
Genital  other sites 
Skin  other sites 
Definitive clinical Screen positive or History positive or both 
Absent Screen negative & History negative 
DS/Uncertain Declined screening (DS) / not screened for the site 
* The presence of scarring was mandatory for a diagnosis of ocular MMP. At the other sites disease may resolve without scarring (particularly in the oral 
mucosa): a history of disease at the extraocular sites was therefore a criterion for a definitive clinical diagnosis  
Table 2 Patient characteristics and direct immunofluorescence status. 
 
Baseline characteristics DIF* positive (n=43) DIF* negative (n=26) DIF* unknown/uncertain (n=4) Significance‡ 
Age of diagnosis in years (range [R], median [M], interquartile range [IQR]) 
[R] 18 - 86, [M] 58, [R] 23 - 82, [M] 60.5, [R] 53 - 70, [M] 66.5, 
p = 0.620§ 
[IQR] 52 - 64 [IQR] 51 - 71 [IQR] 59.5 - 68.5 
Females 14 (32.6%) 12 (46.2%) 1 (25.0%) p = 0.259 II 
Race    
p = 0.566** 
White-British 33 (76.7%) 21 (80.8%) 4 (100.0%) 
White-Irish 2 (4.7%) 0 (0.0%) 0 (0.0%) 
White-Other 2 (4.7%) 1 (3.9%) 0 (0.0%) 
Black-African 0 (0.0%) 1 (3.9%) 0 (0.0%) 
Asian-Indian 1 (2.3%) 1 (3.9%) 0 (0.0%) 
Asian-Pakistani 1 (2.3%) 0 (0.0%) 0 (0.0%) 
Other 1 (2.3%) 2 (7.7%) 0 (0.0%) 
Unknown 3 (7.0%) 0 (0.0%) 0 (0.0%) 
Time from diagnosis in months†† (range [R], median [M], interquartile range 
[IQR]) 
[R] 26 - 325, [M] 87.0, [R] 19 - 345,[M] 123.5, [R] 22 - 173, [M] 87.5, 
p = 0.373§ 
[IQR] 54 – 141 [IQR] 55.5 - 176.5 [IQR] 25.5 - 164.5 
Autoimmune disease‡‡    
p = 0.586 II Yes 16 (37.2%) 8 (30.8%) 3 (75.0%) 
No 27 (62.8%) 18 (69.2%) 1 (25.0%) 
Malignancy    
p >0.999** Yes 6 (14.0%) 3 (11.5%) 0 (0.0%) 
No 37 (86.1%) 23 (88.5%) 4 (100.0%) 
Ocular co-morbidities     
> 0.999** 
0.075** 
> 0.999** 
0.347** 
> 0.999** 
0.0496** 
0.464** 
> 0.999** 
Glaucoma 8 (18.6%) 4 (15.4%) 1 (25.0%) 
Pseudophakia 13 (30.2%) 14 (53.8%) 0 (0.0%) 
Previous lid surgery 21 (48.8%) 13 (50.0%) 1 (25.0%) 
Previous conjunctival surgery 6 (14.0%) 6 (23.1%) 0 (0.0%) 
Previous glaucoma surgery 1 (2.3%) 0 (0.0%) 1 (25.0%) 
Corneal graft 0 (0.0%) 3 (11.5%) 0 (0.0%) 
Other eye surgery 4 (9.3%) 4 (15.4%) 0 (0.0%) 
Other eye disease 1 (2.3%) 1 (3.9%) 0 (0.0%) 
*Direct immunofluorescence results †Oral, nasopharyngeal, skin, anogenital involvement  in various combinations ‡Comparing DIF postive and DIF negative  
§Mann-Whitney U test IIChi-square test **Fisher’s exact test (2-sided) ††Time of follow-up from diagnosis ‡‡Includes thyroid disease, type 1 diabetes mellitus, rheumatoid 
arthritis, psoriasis, lichen planus, Sjogren’s syndrome, systemic lupus erytheomatosuus, atopy, and other autoimmune diseases.  
Table 3 Sites involved*  and patient characteristics of ocular mucous membrane pemphigoid (OcMMP) cases and direct immunofluorescence (DIF) results. 
 
Characteristics  All ocular MMP 
 
Ocular only MMP Ocular & oral MMP Ocular, oral, and nasopharyngeal MMP Ocular + other 
combinations of 
extraocular sites 
involved† 
Total (n) 73 20  19 10 24 
Female 27 (37.0%) 9 (45.0%) 5 (26.3%) 6 (60.0%) 7 (29.2%) 
Age (years)      
Median 60 67.5 58.0 55.0 60.0 
Interquartile range 53 - 68 52 - 77.5 51.0 - 62.0 40.8 - 61.2 55.3 - 68.0 
White race  63 (86.3%) 18 (90.0%) 17 (89.5%) 10 (100.0%) 18 (75.0%) 
Systemic 
immunotherapy 52 (71.2%) 15 (75.0%) 12 (63.2%) 10 (100.0%) 15 (62.5%) 
Asymptomatic of 
site(s) involved - 0 (0.0%) 
Ocular 5 (26.3%)‡ 
Oral 4 (21.1%)§ 
Ocular 0 (0.0%) 
Oral 2 (20.0%) II 
Nasopharyngeal 6 (60.0%)** 
- 
DIF Results: Significantly fewer patients with ocular only MMP were DIF positive (p=0.03)†† 
DIF + 43 (58.9%) 8 (40.0%) 15 (79.0%) 6 (60.0%) 14 (58.3%) 
DIF - 26 (35.6%) 11 (55.0%) 4 (21.1%) 4 (40.0%) 7 (29.2%) 
DIF unknown 4 (5.5%) 1 (5.0%) 0 (0.0%) 0 (0.0%) 3 (12.5%) 
 
DIF + = Direct immunofluorescene positive; DIF - = Direct immunofluorescence negative; *Sites involved detected at the time of this cross-sectional study; some sites may be in remission; †Oral, 
nasopharyngeal, skin, anogenital involvement  in various combinations; ‡5 were DIF +; §3 were DIF + and 1 was DIF -; II2 were DIF -; **4 were DIF + and 2 were DIF -; ††Chi-
square test. 
Table 4 Indices of disease activity and severity for ocular and relationship to direct Immunofluorescence (DIF) findings. 
 
Direct immuno-
fluorescence  
(DIF) result 
OCULAR indices of disease activity and severity (any case of ocular disease +/- other sites involved) 
 Index of ocular disease activity Indices of severity of disease 
Ocular inflammation score ≥ 5* 
(n, %) 
Tauber stage >IIb, IIIb†  
(n, %) 
Central corneal 
conditions‡ 
(n, %) 
History of fornix 
reconstruction or entropion 
surgery  
(n, %) 
Systemic immunotherapy 
ocular patients 
(n, %) 
Positive  16/43  (37.2%) 25/43 (58.1%) 5/43 (11.6%) 25/43 (58.1%) 34/43 (79.1%) 
Negative  12/26 (46.2%) 17/26 (65.4%) 10/26 (38.5%) 21/26 (80.8%) 17/26 (65.4%) 
p-valuesII 0.613 0.617 0.015 0.068 0.262 
 OCULAR indices of disease activity and severity (ocular only disease with no other sites involved) 
 Index of ocular disease activity Indices of severity of disease 
 Ocular inflammation score ≥ 5* 
(n, %) 
Tauber stage >IIb, IIIb†  
(n, %) 
Central corneal 
conditions‡ 
(n, %) 
History of fornix 
reconstruction or entropion 
surgery  
(n, %) 
Systemic immunotherapy 
ocular patients 
(n, %) 
Positive 
5/8 (62.5%) 6/8 (75.0%) 3/8(37.5%) 8/8 (100.0%) 7/8 (87.5%) 
Negative 4/11 (36.4%) 7/11 (63.6%) 5/11 (45.5%) 9/11 (81.8%) 9/11 (81.8%) 
p-valuesII 0.370 >0.999 >0.999 0.485 >0.999 
* Inflammation score using the Moorfields & Institute of Ophthalmology conjunctival inflammation grading system for ocular mucous membrane pemphigoid; score for each bulbar 
conjunctival quadrant 0=None, 0.5-1.0=Minimal, 1.5-2.0=Mild, 3.0-3.5=Moderate, 4.0=Severe (maximum 16 for each eye); †Tauber staging >IIb=lower fornix foreshortening >25%, 
>IIIb=presence of lower lid symblepharon>25%; ‡ Central corneal conditions include central vessels, central scarring, central ulceration, central conjunctivalisation; IIFisher’s exact test (2-
sided).  
